← Back to Clinical Trials
Recruiting NCT07433959

NCT07433959 Neuromodulation to Improve Grasping Function After SCI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07433959
Status Recruiting
Phase
Sponsor State University of New York at Buffalo
Condition Spinal Cord Injury
Study Type INTERVENTIONAL
Enrollment 54 participants
Start Date 2026-04-01
Primary Completion 2027-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
iTBSSham iTBSPCMS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 54 participants in total. It began in 2026-04-01 with a primary completion date of 2027-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to restore the activities of late descending signals with a noninvasive stimulation approach in combination with hand motor training to improve hand function in persons with cervical SCI. The main question it aims to answer is if the inputs to late descending signals above the level of injury and the output of residual late descending signals below the level of injury could be increased. Specifically, in the first part of the study, 30 participants will complete 2 randomized sessions to compare the effect of intermittent theta burst stimulation combined with paired corticospinal motoneuronal stimulation. In the second part of the study, 24 participants will complete either combined stimulation protocol or sham stimulation protocol with exercise training.

Eligibility Criteria

Inclusion Criteria: For individuals with SCI: * Ages 18-75 years * Chronic SCI (≥1 year of injury) * Cervical injury at C8 or above * Individuals who have MEP responses in at least one FDI muscle Exclusion Criteria: * Uncontrolled medical problems including pulmonary or cardiovascular disease * Premorbid, ongoing major depression or psychosis, altered cognitive status * History of head injury or stroke * Metal plate in skull * History of seizures * Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs * Pregnant females * Individuals who suffer from a spinal cord disease such as spinal stenosis, spinal bifida or herniated cervical

Contact & Investigator

Central Contact

Hang Jin Jo, PhD

✉ hangjinj@buffalo.edu

📞 716-829-2905

Frequently Asked Questions

Who can join the NCT07433959 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Spinal Cord Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07433959 currently recruiting?

Yes, NCT07433959 is actively recruiting participants. Contact the research team at hangjinj@buffalo.edu for enrollment information.

Where is the NCT07433959 trial being conducted?

This trial is being conducted at Buffalo, United States.

Who is sponsoring the NCT07433959 clinical trial?

NCT07433959 is sponsored by State University of New York at Buffalo. The trial plans to enroll 54 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology